Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound

2001 ◽  
Vol 16 (5) ◽  
pp. 292-297 ◽  
Author(s):  
C. Sloots ◽  
R. Felt-Bersma ◽  
A. Poen ◽  
M. Cuesta ◽  
S. Meuwissen
2020 ◽  
Vol 13 ◽  
pp. 175628482096873
Author(s):  
Si-Nan Lin ◽  
Dan-Ping Zheng ◽  
Yun Qiu ◽  
Sheng-Hong Zhang ◽  
Yao He ◽  
...  

Background: A suitable disease classification is essential for individualized therapy in patients with Crohn’s disease (CD). Although a potential mechanistic classification of colon-involving and non-colon-involving disease was suggested by recent genetic and microbiota studies, the clinical implication has seldom been investigated. We aimed to explore the association of this colonic-based classification with clinical outcomes in patients with CD compared with the Montreal classification. Methods: This was a retrospective study of CD patients from a tertiary referral center. Patients were categorized into colon-involving and non-colon-involving disease, and according to the Montreal classification. Clinico-demographic data, medications, and surgeries were compared between the two classifications. The primary outcome was the need for major abdominal surgery. Results: Of 934 patients, those with colonic involvement had an earlier median (interquartile range) age of onset [23.0 (17.0–30.0) versus 26.0 (19.0–35.0) years, p = 0.001], higher frequency of perianal lesions (31.2% versus 14.5%, p < 0.001) and extraintestinal manifestations (21.8% versus 14.5%, p = 0.010), but lower frequency of stricture (B2) (16.3% versus 24.0%, p = 0.005), than those with non-colon-involving disease. Colon-involving disease was a protective factor against major abdominal surgery [hazard ratio, 0.689; 95% confidence interval (CI), 0.481–0.985; p = 0.041]. However, patients with colon-involving CD were more prone to steroids [odds ratio (OR), 1.793; 95% CI, 1.206–2.666; p = 0.004] and azathioprine/6-mercaptopurine (AZA/6-MP) treatment (OR, 1.732; 95% CI, 1.103–2.719; p = 0.017) than were patients with non-colon-involving disease. The Montreal classification was not predictive of surgery or steroids and AZA/6-MP treatment. Conclusion: This study supports the rationale for disease classification based on the involvement of colon. This new classification of CD is a better predictor of clinical outcomes than the Montreal classification.


2002 ◽  
Vol 122 (4) ◽  
pp. 854-866 ◽  
Author(s):  
Tariq Ahmad ◽  
Alessandro Armuzzi ◽  
Mike Bunce ◽  
Kim Mulcahy–Hawes ◽  
Sara E. Marshall ◽  
...  

2007 ◽  
Vol 52 (6) ◽  
pp. 1405-1409 ◽  
Author(s):  
Cheol Hee Park ◽  
Jin Oh Kim ◽  
Myung-Gyu Choi ◽  
Kyung Jo Kim ◽  
Young-Ho Kim ◽  
...  

2000 ◽  
Vol 118 (4) ◽  
pp. A583
Author(s):  
Vera Leotta ◽  
Giustina Milite ◽  
Maddalena Zippi ◽  
Alessandra Mancini ◽  
Giuseppina Cadau ◽  
...  

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S138-S138
Author(s):  
T Fujii ◽  
Y Kitazume ◽  
K Takenaka ◽  
K Suzuki ◽  
M Motobayashi ◽  
...  

2020 ◽  
Vol 14 (11) ◽  
pp. 1572-1580
Author(s):  
Carlo Morasso ◽  
Marta Truffi ◽  
Renzo Vanna ◽  
Sara Albasini ◽  
Serena Mazzucchelli ◽  
...  

Abstract Backgrounds and Aims There is no accurate and reliable circulating biomarker to diagnose Crohn’s disease [CD]. Raman spectroscopy is a relatively new approach that provides information on the biochemical composition of samples in minutes and virtually without any sample preparation. We aimed to test the use of Raman spectroscopy analysis of plasma samples as a potential diagnostic tool for CD. Methods We analysed by Raman spectroscopy dry plasma samples obtained from 77 CD patients [CD] and 45 healthy controls [HC]. In the dataset obtained, we analysed spectra differences between CD and HC, as well as among CD patients with different disease behaviours. We also developed a method, based on principal component analysis followed by a linear discrimination analysis [PCA-LDA], for the automatic classification of individuals based on plasma spectra analysis. Results Compared with HC, the CD spectra were characterised by less intense peaks corresponding to carotenoids [p &lt;10–4] and by more intense peaks corresponding to proteins with β-sheet secondary structure [p &lt;10–4]. Differences were also found on Raman peaks relative to lipids [p = 0.0007] and aromatic amino acids [p &lt;10–4]. The predictive model we developed was able to classify CD and HC subjects with 83.6% accuracy [sensitivity 80.0% and specificity 85.7%] and F1-score of 86.8%. Conclusions Our results indicate that Raman spectroscopy of blood plasma can identify metabolic variations associated with CD and it could be a rapid pre-screening tool to use before further specific evaluation.


2014 ◽  
Vol 13 (4-5) ◽  
pp. 467-471 ◽  
Author(s):  
Martin W. Laass ◽  
Dirk Roggenbuck ◽  
Karsten Conrad

2016 ◽  
Vol 18 (4) ◽  
pp. 351-356 ◽  
Author(s):  
Y. Nasseri ◽  
L. Cassella ◽  
M. Berns ◽  
K. Zaghiyan ◽  
J. Cohen

Sign in / Sign up

Export Citation Format

Share Document